Company intelligence / Profile preview

Helion Biotech ApS

Lyngby, Capital Region of Denmark, Denmark

Ownership: Private
Development stage: Other

Overview

Helion Biotech has a Phase II-ready replacement therapy with recombinant human MBL (rhMBL) for treating inherited immune defects. The therapy is supported by over 10 independent clinical publications since 2006 linking MBL deficiency to high risk of neonatal infection and sepsis. A complete US regulatory dossier enables direct entry into a Phase II clinical trial, and additional expansion to other immunocompromised indications is proposed.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Helion Biotech ApS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helion Biotech ApS.

Explore the full profile